Rapport Therapeutics, Inc. (RAPP)
NASDAQ: RAPP · Real-Time Price · USD
10.47
+0.22 (2.15%)
At close: May 12, 2025, 4:00 PM
10.47
0.00 (0.00%)
After-hours: May 12, 2025, 4:02 PM EDT

Rapport Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22
Net Income
-79.7-78.31-34.79-11.62
Depreciation & Amortization
0.930.840.110.02
Asset Writedown & Restructuring Costs
---5.45
Loss (Gain) From Sale of Investments
-2.67-3.21-0.08-
Stock-Based Compensation
12.7810.243.530.61
Other Operating Activities
0.98.031.390.38
Change in Accounts Payable
0.97-0.350.861.58
Change in Other Net Operating Assets
-0.67-2.071.80.05
Operating Cash Flow
-67.45-64.83-27.18-3.54
Capital Expenditures
-1.62-2.41-1.64-0.31
Sale (Purchase) of Intangibles
----5.45
Investment in Securities
-105.56-167.74-77.22-
Investing Cash Flow
-107.18-170.14-78.86-5.76
Total Debt Issued
---8.73
Net Debt Issued (Repaid)
---8.73
Issuance of Common Stock
157.72157.710.050.03
Repurchase of Common Stock
-0--0-
Other Financing Activities
0.28--0.13-0.11
Financing Cash Flow
157.97221.63145.1443.29
Net Cash Flow
-16.66-13.3439.133.99
Free Cash Flow
-69.07-67.23-28.82-3.85
Free Cash Flow Per Share
-2.38-3.24-19.14-4.95
Levered Free Cash Flow
-47-44.47-17.43-
Unlevered Free Cash Flow
-47-44.47-17.43-
Change in Net Working Capital
0.931.23-3.19-
Updated May 8, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q